COVID-19 Offerings COVID-19 Diagnostic Offerings

COVID-19 Diagnostic Offerings

background pattern

Standard BioTools Has Developed a High-Throughput  Extraction-Free Diagnostic Test for the Detection of SARS-CoV-2 in Saliva

The Advanta™ Dx SARS-CoV-2 RT-PCR Assay is a qPCR-based test that, by taking advantage of Standard BioTools™ proprietary microfluidics technology and the Juno™ and Biomark™ HD systems, enables reliable, high-capacity testing of saliva samples from patients suspected by their health care providers of COVID-19 (coronavirus) infection to support diagnostic decision making.

The assay has been authorized for use under FDA Emergency Use Authorization (EUA).

 

 

 

Learn more about the Advanta Dx SARS-CoV-2 RT-PCR Assay.

Customers in US

 

Test Platform Highlights

  • Saliva-based test: The test performs equivalently to comparator nasal tests but utilizes convenient and noninvasive sample collection.
  • Easy supply chain burden: Saliva can be collected using any sterile, preservative-free sample container, and the extraction-free workflow eliminates the need for viral RNA extraction kits.
  • Lower sample volume requirements: Our microfluidic workflow uses an industry-leading 15 µL of sample input, 10x less than traditional microwell reverse transcription PCR methods, improving sample acceptance rates and preserving precious samples for use in other applications.
  • High test capacity: Modular platform supports concurrent parallel runs to test up to 6,000* samples and controls per day per instrument.

* Actual results may vary based upon the following factors, including but not limited to: laboratory processes, workflows, equipment and the number of operators.

Want more information? 

Learn more about advantages of saliva-based testing.


Learn more

Learn how Standard BioTools is helping schools and businesses with critical testing needs.

Community Connect

There’s an urgent need to simplify testing for COVID-19 so that people who are infected can be easily and quickly identified. The test we developed in collaboration with Standard BioTools doesn’t require RNA extraction, a time-consuming and expensive step necessary to other tests for SARS-CoV-2. Our test could be easily scaled up and made widely available.

– Richard Head | Director of the Genome Technology Access Center at the McDonnell Genome Institute

Get more information about the Advanta Dx SARS-CoV-2 RT-PCR Assay.

Unless explicitly and expressly stated otherwise, all products are provided for Research Use Only, not for use in diagnostic procedures. Find more information here.